Invitrogen Predicts Technology Will Revolutionize Genomics | GenomeWeb

CARLSBAD, Calif.--A new Invitrogen technology that can be used to rapidly clone and express genes will expedite functional validation to keep pace with strides being made in structural genomics and DNA chip-based expressional analysis, according to Invitrogen CEO Lyle Turner. The proprietary technology, amenable to any gene collection, was first tested using the yeast genome. Since October 1997, Invitrogen has cloned 6,000 and expressed 1,000 yeast genes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.